An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: Results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands

Cornelis Boersma*, George W. Carides, Jarir Atthobari, Adriaan A. Voors, Maarten J. Postma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)
188 Downloads (Pure)

Abstract

Background: The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH). Compared with atenolol, losartan reduced the combined risk for CVD-related morbidity and mortality by 13% (P = 0.021), and reduced the risk for stroke by 25% (P = 0.001), with comparable blood pressure control in both trial arms.

Objective: The aim of this study was to analyze the cost-effectiveness of losartan compared with atenolol in the treatment of stroke from the Dutch health care perspective.

Methods: Utilization of losartan and atenolol within the trial period (mean, 4.8 years) and an estimation of direct medical costs of stroke for The Netherlands were combined with estimates of reduction in life expectancy through stroke. Medication costs and stroke incidence during 5.5 years of patient follow-up were estimated separately, adjusted for the baseline degree of LVH and Framingham risk score. To estimate lifetime stroke costs, the cumulative incidence of stroke was multiplied by the lifetime direct medical costs attributable to stroke. All costs are in 2006 Dutch prices and discounted following the former (4% costs and effects) and new Dutch guideline (4% costs, 1.5% effects) for conducting pharmacoeconomic analyses.

Results: With 4% discounting, prevention of stroke was associated with a gain of 3.7 life-years. As a consequence, losartan treatment was associated with 0.059 life-year gained (LYG) per patient treated with losartan. Losartan reduced stroke-related costs by 1076EURO (US $1349) per patient. After inclusion of study medication cost, net cost per patient was 51EURO ($64) higher for losartan than atenolol. The net cost per LYG was 864EURO ($1083), which is below the Dutch pharmacoeconomic threshold of 20,000EURO/LYG (-$25,000/LYG) for accepting interventions. The corresponding probability of a costeffectiveness ratio below this Dutch threshold was 0.95. Discounting money and health following the new Dutch guideline resulted in an even more favorable cost-effectiveness for losartan.

Conclusions: Results from the present analysis suggest that, in The Netherlands, treatment with losartan compared with atenolol may well be a cost-effective intervention based on the reduced risk for stroke observed in the LIFE trial.

Original languageEnglish
Pages (from-to)963-971
Number of pages9
JournalClinical Therapeutics
Volume29
Issue number5
DOIs
Publication statusPublished - May-2007

Keywords

  • angiotensin-II receptor blocker
  • losartan
  • stroke
  • cost-effectiveness
  • COST-EFFECTIVENESS
  • STROKE
  • MORTALITY
  • DISEASE
  • CARE
  • NEPHROPATHY
  • PERSPECTIVE
  • PREVENTION
  • PATTERNS
  • DECLINE

Cite this